Regeneron Reports Strong Q2 Earnings with Revenue Growth and Record Sales
Regeneron (REGN) reported second-quarter revenue of $4.3 billion in July 2026, a 17% increase compared to the same period in 2025. The company's non-GAAP earnings per share were $14.29, up 11%. Key drivers included record sales for Dupixent and EYLEA HD, with global Dupixent revenue reaching $6 billion—a 38% increase—and U.S. sales rising by 42%. Libtayo also saw strong performance globally at $489 million in sales. The company repaid its full development balance of approximately $3.1 billion to Sanofi, which is expected to boost collaboration revenue starting in Q3. Regeneron's cash position stood at $15.1 billion as of June 30, and it spent $1.2 billion on share buybacks during the quarter. However, EYLEA U.S. sales declined by 45% due to patient transition to HD versions and competition. Despite these gains, Regeneron faced some challenges including a temporary manufacturing disruption in Ireland that impacted GAAP gross margin (78%), as well as unmet primary endpoints for the fianlimab melanoma program.
Topics: dupixent_sales eylea_sales libtayo_sales pharmaceuticals revenue_growth